Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Total Long Term Liabilities 2010-2024 | CYDY

CytoDyn total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  
CytoDyn Annual Total Long Term Liabilities
(Millions of US $)
2024 $44
2023 $1
2022 $0
2021 $1
2020 $8
2019 $3
2018 $1
2017 $3
2016 $
2015 $5
2014 $2
2013 $1
2012 $
2011 $0
2010 $0
2009 $1
CytoDyn Quarterly Total Long Term Liabilities
(Millions of US $)
2024-08-31 $44
2024-05-31 $44
2024-02-29 $0
2023-11-30 $0
2023-08-31 $0
2023-05-31 $1
2023-02-28 $0
2022-11-30 $0
2022-08-31 $0
2022-05-31 $0
2022-02-28 $0
2021-11-30 $0
2021-08-31 $1
2021-05-31 $1
2021-02-28 $1
2020-11-30 $35
2020-08-31 $14
2020-05-31 $8
2020-02-29 $2
2019-11-30 $2
2019-08-31 $2
2019-05-31 $3
2019-02-28 $4
2018-11-30 $4
2018-08-31 $5
2018-05-31 $1
2018-02-28 $3
2017-11-30 $3
2017-08-31 $3
2017-05-31 $3
2017-02-28 $4
2016-11-30 $4
2016-08-31
2016-05-31
2016-02-29
2015-11-30
2015-08-31
2015-05-31 $5
2015-02-28 $2
2014-11-30 $3
2014-08-31 $3
2014-05-31 $2
2014-02-28 $2
2013-11-30 $2
2013-08-31 $1
2013-05-31 $1
2013-02-28 $1
2012-11-30 $0
2012-08-31 $0
2012-05-31
2012-02-29 $0
2011-11-30 $1
2011-08-31 $0
2011-05-31 $0
2011-02-28 $0
2010-11-30 $0
2010-08-31 $0
2010-05-31 $0
2010-02-28 $0
2009-11-30 $0
2009-08-31 $0
2009-05-31 $1
2009-02-28 $1
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.140B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.838B 30.72
Takeda Pharmaceutical (TAK) Japan $42.573B 8.86
Sandoz Group AG (SDZNY) Switzerland $19.533B 0.00
Merck (MKKGY) Germany $19.083B 17.09
Astellas Pharma (ALPMY) Japan $18.260B 16.82
United Therapeutics (UTHR) United States $16.648B 16.38
Summit Therapeutics (SMMT) United States $14.012B 0.00
Neurocrine Biosciences (NBIX) United States $12.722B 33.69
Shionogi (SGIOY) Japan $12.010B 11.51
Catalent (CTLT) United States $11.069B 0.00
Madrigal Pharmaceuticals (MDGL) United States $7.578B 0.00
Orion OYJ (ORINY) Finland $6.653B 18.71
Corcept Therapeutics (CORT) United States $6.029B 45.67
Ionis Pharmaceuticals (IONS) United States $5.370B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.199B 0.00
PTC Therapeutics (PTCT) United States $3.334B 0.00
Dyne Therapeutics (DYN) United States $3.021B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.600B 15.54
Catalyst Pharmaceuticals (CPRX) United States $2.562B 11.61
Soleno Therapeutics (SLNO) United States $2.491B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.247B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.866B 0.00
Xencor (XNCR) United States $1.750B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.634B 0.00
Evotec AG (EVO) Germany $1.591B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.574B 0.00
Harrow (HROW) United States $1.528B 0.00
Indivior (INDV) United States $1.500B 6.11
Guardian Pharmacy Services (GRDN) United States $1.461B 0.00
Ocular Therapeutix (OCUL) United States $1.388B 0.00
ARS Pharmaceuticals (SPRY) United States $1.361B 0.00
Cassava Sciences (SAVA) United States $1.274B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.269B 0.00
Ardelyx (ARDX) United States $1.258B 0.00
Enliven Therapeutics (ELVN) United States $1.199B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.124B 0.00
Collegium Pharmaceutical (COLL) United States $0.966B 5.27
Bioventus (BVS) United States $0.950B 30.03
Cronos Group (CRON) Canada $0.795B 0.00
Relay Therapeutics (RLAY) United States $0.795B 0.00
USANA Health Sciences (USNA) United States $0.760B 14.10
Oruka Therapeutics (ORKA) United States $0.726B 0.00
Elite Pharmaceuticals (ELTP) United States $0.659B 0.00
Altimmune (ALT) United States $0.617B 0.00
Tourmaline Bio (TRML) United States $0.590B 0.00
Savara (SVRA) United States $0.577B 0.00
OmniAb (OABI) United States $0.554B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.551B 0.00
Organogenesis (ORGO) United States $0.537B 0.00
Zevra Therapeutics (ZVRA) United States $0.512B 0.00
Esperion Therapeutics (ESPR) United States $0.497B 0.00
ProKidney (PROK) United States $0.493B 0.00
Korro Bio (KRRO) United States $0.490B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.466B 0.00
Siga Technologies (SIGA) United States $0.463B 5.40
Xeris Biopharma Holdings (XERS) United States $0.461B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.459B 186.00
KalVista Pharmaceuticals (KALV) United States $0.439B 0.00
Aquestive Therapeutics (AQST) United States $0.416B 0.00
Verve Therapeutics (VERV) United States $0.411B 0.00
Akebia Therapeutics (AKBA) United States $0.410B 0.00
Larimar Therapeutics (LRMR) United States $0.393B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.361B 0.00
4D Molecular Therapeutics (FDMT) United States $0.360B 0.00
Avita Medical (RCEL) United States $0.350B 0.00
Sage Therapeutics (SAGE) United States $0.316B 0.00
Nature's Sunshine Products (NATR) United States $0.296B 17.58
Aldeyra Therapeutics (ALDX) United States $0.289B 0.00
Aclaris Therapeutics (ACRS) United States $0.271B 0.00
Lyell Immunopharma (LYEL) United States $0.265B 0.00
Lexeo Therapeutics (LXEO) United States $0.214B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.213B 0.00
Silence Therapeutics (SLN) United Kingdom $0.210B 0.00
Acrivon Therapeutics (ACRV) United States $0.204B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.198B 0.00
Nektar Therapeutics (NKTR) United States $0.194B 0.00
Profound Medical (PROF) Canada $0.186B 0.00
Nanobiotix S.A (NBTX) France $0.179B 0.00
MediWound (MDWD) Israel $0.178B 0.00
Galectin Therapeutics (GALT) United States $0.174B 0.00
Heron Therapeutics (HRTX) United States $0.163B 0.00
Inhibikase Therapeutics (IKT) United States $0.155B 0.00
Achieve Life Sciences (ACHV) Canada $0.148B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Cardiol Therapeutics (CRDL) Canada $0.132B 0.00
Telomir Pharmaceuticals (TELO) United States $0.126B 0.00
Pyxis Oncology (PYXS) United States $0.113B 0.00
Journey Medical (DERM) United States $0.112B 0.00
Karyopharm Therapeutics (KPTI) United States $0.106B 0.00
Avalo Therapeutics (AVTX) United States $0.105B 0.00
Context Therapeutics (CNTX) United States $0.104B 0.00
Century Therapeutics (IPSC) United States $0.103B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Fractyl Health (GUTS) United States $0.101B 0.00
Regulus Therapeutics (RGLS) United States $0.096B 0.00
Inotiv (NOTV) United States $0.093B 0.00
Assertio Holdings (ASRT) United States $0.090B 23.52
Arch Biopartners (ACHFF) Canada $0.090B 0.00
Relmada Therapeutics (RLMD) United States $0.084B 0.00
PMV Pharmaceuticals (PMVP) United States $0.083B 0.00
ESSA Pharma (EPIX) Canada $0.081B 0.00
Vivani Medical (VANI) United States $0.079B 0.00
CASI Pharmaceuticals (CASI) China $0.079B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
ElectroCore (ECOR) United States $0.073B 0.00
OptiNose (OPTN) United States $0.072B 0.00
Metagenomi (MGX) United States $0.071B 0.00
Scienture Holdings (SCNX) United States $0.065B 0.00
AlloVir (ALVR) United States $0.064B 0.00
Champions Oncology (CSBR) United States $0.062B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
Unicycive Therapeutics (UNCY) United States $0.055B 0.00
BioVie (BIVI) United States $0.054B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Prelude Therapeutics (PRLD) United States $0.052B 0.00
Iterum Therapeutics (ITRM) Ireland $0.050B 0.00
Protara Therapeutics (TARA) United States $0.049B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
Gain Therapeutics (GANX) United States $0.046B 0.00
SCYNEXIS (SCYX) United States $0.046B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.045B 0.00
VYNE Therapeutics (VYNE) United States $0.045B 0.00
FibroGen (FGEN) United States $0.040B 0.00
Tempest Therapeutics (TPST) United States $0.040B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.036B 0.00
Incannex Healthcare (IXHL) Australia $0.035B 0.00
Carisma Therapeutics (CARM) United States $0.034B 0.00
CERo Therapeutics Holdings (CERO) United States $0.033B 0.00
DURECT (DRRX) United States $0.031B 0.00
Surrozen (SRZN) United States $0.030B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.028B 0.00
Lipocine (LPCN) United States $0.028B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Citius Pharmaceuticals (CTXR) United States $0.024B 0.00
BioLineRx (BLRX) Israel $0.022B 0.00
GlycoMimetics (GLYC) United States $0.020B 0.00
Enlivex Therapeutics (ENLV) Israel $0.020B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
ProPhase Labs (PRPH) United States $0.018B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Mannatech (MTEX) United States $0.016B 0.00
TherapeuticsMD (TXMD) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.016B 0.00
Vivos Therapeutics (VVOS) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.015B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.015B 0.00
Traws Pharma (TRAW) United States $0.014B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.013B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Jaguar Animal Health (JAGX) United States $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
Conduit Pharmaceuticals (CDT) United States $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Indaptus Therapeutics (INDP) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.007B 0.00
Ainos (AIMD) United States $0.006B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Biomerica (BMRA) United States $0.005B 0.00
Aditxt (ADTX) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Aptorum Group (APM) United Kingdom $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.004B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Molecular Templates (MTEM) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 1.77
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.53